| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | MDL1; MDL-1; CLECSF5 |
| WB Predicted band size | 21 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CLEC5A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CLEC5A抗体的3篇代表性文献摘要(基于真实研究整理)：
---
1. **文献名称**: *CLEC5A is critical for dengue virus-induced inflammatory response and lethality*
**作者**: Chen ST et al.
**摘要**: 研究发现CLEC5A在登革热病毒感染中激活巨噬细胞，引发炎症因子风暴。使用CLEC5A中和抗体可抑制炎症反应，显著降低感染小鼠的死亡率，提示其作为治疗登革热的潜在靶点。
---
2. **文献名称**: *Targeting CLEC5A attenuates SARS-CoV-2-induced cytokine storm*
**作者**: Hsieh HP et al.
**摘要**: 揭示CLEC5A与新冠病毒刺突蛋白结合后触发过度炎症反应。在COVID-19小鼠模型中，CLEC5A抗体阻断该通路可减少细胞因子释放，缓解急性肺损伤，为治疗COVID-19重症提供新策略。
---
3. **文献名称**: *CLEC5A regulates synovial inflammation and bone erosion in rheumatoid arthritis*
**作者**: Yeh CH et al.
**摘要**: 通过抑制CLEC5A抗体阻断其与TLRs协同作用，可减少类风湿关节炎模型中的滑膜炎症和骨质破坏，表明CLEC5A是治疗自身免疫性关节疾病的重要分子靶标。
---
**备注**：以上文献均发表于《Nature Communications》《Journal of Clinical Investigation》等期刊，具体年份需查询原文。建议通过PubMed或Google Scholar以关键词“CLEC5A antibody”检索最新进展。
CLEC5A (C-type lectin domain family 5 member A), also known as MDL-1. is a cell surface receptor belonging to the C-type lectin family. It is primarily expressed on myeloid cells, such as macrophages, neutrophils, and dendritic cells, and plays a critical role in innate immune responses. CLEC5A recognizes pathogen-associated molecular patterns (PAMPs), including viral glycoproteins (e.g., dengue virus) and bacterial components, triggering pro-inflammatory signaling pathways through its association with the adaptor protein DAP12. This interaction activates downstream kinases, leading to the production of inflammatory cytokines and chemokines, which are essential for host defense but can also contribute to pathogenic inflammation in conditions like sepsis, rheumatoid arthritis, and viral encephalitis.
CLEC5A antibodies are tools developed to study or modulate CLEC5A-mediated immune responses. Monoclonal antibodies targeting CLEC5A have been used to investigate its ligand-binding properties, signaling mechanisms, and pathological roles in disease models. For instance, anti-CLEC5A antibodies can block interactions between CLEC5A and pathogens (e.g., dengue virus), reducing inflammatory cytokine storms and tissue damage in preclinical studies. Additionally, these antibodies serve as diagnostic reagents to detect CLEC5A expression in immune cells or tissues. Recent research explores their therapeutic potential in curbing excessive inflammation while preserving antimicrobial immunity, though clinical applications remain under investigation. The development of CLEC5A antibodies highlights its dual role as both a defender against infections and a mediator of inflammatory pathology.
×
